RxDoctor Payments Data

Anita Ahmed, MD

Family Medicine · Ocoee, FLNPI 1013337898

Payments from drug & device makers

$7,989in general payments, 2019–2025

Across 411 payments — averaging $19.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • AbbVie$1K
  • Lilly USA, LLC$784
  • Novo Nordisk$680
  • Pfizer$588
  • Boehringer Ingelheim$509
  • plus $3K from 32 others

What the payments were for

  • Food & beverage$7,983100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,989 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$38,140
Medicare patients
87
Services billed
321

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide15$30,897
OzempicSemaglutide12$22,710
JanuviaSitagliptin Phosphate19$19,113
JardianceEmpagliflozin14$18,417
EliquisApixaban15$18,037
Atorvastatin Calcium175$1,573
Losartan Potassium101$1,082
Levothyroxine Sodium84$1,068
Rosuvastatin Calcium95$1,062
Pantoprazole Sodium65$682
Amlodipine Besylate93$619
Fluticasone Propionate32$589
Lisinopril70$564
Metformin Hcl87$546
Metoprolol Succinate33$493

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$784$30,89715 claims
Novo NordiskOzempic$680$22,71012 claims
MerckJanuvia$125$19,11319 claims
Boehringer IngelheimJardiance$509$18,41714 claims
PfizerEliquis$588$18,03715 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$13$1,06884 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Ocoee

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →